The paper “Efficacy and safety of boron neutron capture therapy for Hypopharyng……
Treatment results of unresectable, locally recurrent or locally advanced head and neck cancer published
A paper containing the treatment results of unresectable, locally recurrent or ……
Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma
Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……
Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy
Business France Japan Office of the French Embassy in Japan engages in building……
On 25th September, the Groundbreaking Ceremony for the Boao BNCT center has tak……
Stella Pharma Presented at Side Events of the 66th IAEA General Conference
The 66th International Atomic Energy Agency (IAEA) General Conference is being ……
Stella Pharma Corporation was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2022
Informa Pharma Intelligence has announced that Stella Pharma is a nominee f……
“Destroying Cancer with Boron and Neutrons” will be on NHK WORLD-JAPAN
Japan's public media organization NHK (Japan Broadcasting Corporation) will bro……
Interview published on Science Japan, online magazine| Japan’s “Fifth Cancer Treatment,” BNCT, Finally Off the Ground
Here is a featured story on BNCT (Boron Neutron Capture Therapy) boron drug dev……
The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”
The title is “Accelerator-based BNCT for patients with recurrent glioblastoma: ……
The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”
The title is "Boron neutron capture therapy using cyclotron-based epithermal ne……